8-K: Serina Secures $20M Convertible Note for Parkinson's Study

Serina Therapeutics, Inc. has secured up to $20 million in financing via a convertible note and warrants from board member Gregory H. Bailey, M.D., to fund its advanced Parkinson's Disease clinical study.

Summary

• Serina Therapeutics, Inc. entered into an unsecured convertible note agreement for up to $20 million with Gregory H. Bailey, M.D., a member of its Board of Directors.
• The financing is structured in five tranches, tied to specific clinical and operational milestones for the SER-252-1b registrational clinical study in advanced Parkinson's Disease.
• The initial tranche of up to $5 million is available by September 30, 2025, with subsequent tranches totaling $15 million available upon achieving patient enrollment and dosing milestones through April 30, 2026.
• The convertible note bears interest at an annual rate of 10%, with initial interest payable on the first anniversary of funding, then quarterly.
• The note has a maturity date of five years after the initial funding (September 9, 2030) and can be prepaid by the company without penalty.
• The note is convertible into common stock at the holder's option at a conversion price of $5.18 per share.
• Warrants will be issued on each funding date, providing 100% coverage of the loan funds, with an exercise price of $5.44 per share.
• The warrants expire on the earlier of 60 days following the achievement of Milestone 5 (first patient in Cohort 2) or September 30, 2026, but will be extended if shareholder approval is pending.
• Conversion of the note and exercise of warrants are subject to NYSE American rules, limiting issuance to 19.99% of outstanding common stock without shareholder approval. The company will seek this approval at its 2025 annual meeting, and the lender has committed to vote in favor.
• The transaction was approved by a Special Committee of independent and disinterested directors due to the related party nature of the financing.

Sentiment

Score: 7

Explanation: The financing provides crucial capital for the company's lead clinical program, which is a significant positive for a clinical-stage biotech. The milestone-based structure and related-party support are favorable for securing funds. However, the high interest rate, potential for dilution, and reliance on shareholder approval for full conversion/exercise introduce some cautionary elements.

Positives

• Secured up to $20 million in financing, providing critical capital for the SER-252-1b registrational clinical study.
• The financing is milestone-based, aligning funding with clinical progress and de-risking the investment.
• The company retains the discretion to draw funds, except when cash is insufficient to reach the next milestone, providing some operational flexibility.
• The company can prepay the convertible note at any time without penalty.
• The lender, Gregory H. Bailey, M.D., a board member and associated with the largest shareholder (Juvenescence), demonstrates continued support and confidence in the company's clinical program.
• The lender has committed to vote in favor of the necessary shareholder approval for equity issuance, increasing the likelihood of obtaining it.

Negatives

• The financing is from a related party (board member and largest shareholder), which can raise concerns about potential conflicts of interest, despite Special Committee approval.
• The interest rate of 10% per annum is relatively high, indicating a potentially higher cost of capital.
• The company is required to draw funds if it determines it does not have sufficient cash to reach the next milestone, which could limit financial flexibility.
• The conversion of the note and exercise of warrants are subject to shareholder approval for issuances exceeding 19.99% of outstanding common stock, introducing a potential delay or hurdle for full conversion/exercise.
• The warrants are not listed on any quotation system or traded on any securities exchange, limiting their liquidity for the holder.
• The company is restricted from incurring additional senior or pari passu indebtedness without lender consent, potentially limiting future financing options.

Risks

• Clinical Trial Risk: The funding tranches are contingent on achieving specific clinical milestones (patient enrollment, dosing in cohorts 1 and 2 of the SER-252-1b study). Failure to meet these milestones could halt further funding.
• Shareholder Approval Risk: The full conversion of the note and exercise of warrants are contingent on obtaining shareholder approval for equity issuances exceeding 19.99% of outstanding common stock. Failure to obtain this approval could limit the lender's ability to convert/exercise and potentially impact future financing.
• Dilution Risk: Conversion of the note and exercise of warrants will result in dilution for existing shareholders.
• Liquidity Risk: The company is required to draw funds if it lacks sufficient cash for projected costs to reach the next milestone, indicating potential ongoing liquidity needs.
• Related Party Risk: While approved by a Special Committee, the significant financing from a related party (board member, largest shareholder) could still be perceived as a governance risk or create potential conflicts of interest.
• Regulatory Risk: The securities were issued under an exemption from registration (Section 4(a)(2) and Rule 506(b)), and the company will need to file a resale registration statement by January 31, 2026, for the shares.
• Default Risk: The note contains customary events of default, including failure to pay, non-compliance with covenants, incorrect representations, and bankruptcy events, which could trigger immediate repayment.

Future Outlook

The company anticipates progressing its SER-252-1b registrational clinical study for advanced Parkinson's Disease, with funding tranches tied to key milestones including patient enrollment and dosing in Cohort 1 and Cohort 2, expected to extend through April 2026. The company also plans to seek shareholder approval for equity issuances related to the financing at its 2025 annual meeting and file a resale registration statement by January 31, 2026.

Management Comments

• The Company's Board of Directors established and delegated to a special committee comprised solely of independent and disinterested directors (the Special Committee) the power and authority to evaluate, negotiate and approve, or decline to approve, the Convertible Note and the related transactions.
• On September 9, 2025, the Special Committee approved the execution and delivery by the Company of the Convertible Note and the related transaction documents.

Industry Context

This financing provides critical capital for Serina Therapeutics, a biotechnology company, to advance its clinical-stage asset, SER-252, for advanced Parkinson's Disease. The milestone-based funding structure is common in the biotech industry, where significant capital is required for clinical development, and investors often seek to de-risk their investments by tying funding to successful achievement of development milestones. The involvement of a board member and largest shareholder as the lender highlights the challenges smaller biotech firms can face in securing non-dilutive or less dilutive financing from traditional sources, often relying on insider funding to bridge development gaps.

Comparison to Industry Standards

• The 10% interest rate on the convertible note is on the higher side for corporate debt, but may be considered within a reasonable range for a clinical-stage biotechnology company with significant R&D expenses and no commercial products, especially when sourced from a related party. For example, similar stage companies might secure venture debt in the 8-15% range, often with equity kickers.
• The warrant coverage of 100% and an exercise price at 105% of the conversion price is a common equity kicker in venture debt or convertible note financings for early to mid-stage biotech companies, reflecting the risk profile.
• The milestone-based funding structure is a standard practice in biotech financing, allowing the company to access capital as it achieves specific clinical development goals, such as patient enrollment and cohort dosing, which are critical de-risking events. This is comparable to how venture capital firms structure investments in clinical-stage companies.
• The requirement for shareholder approval for equity issuances exceeding 19.99% is a standard NYSE American (and other major exchanges) listing rule (e.g., Section 713 of the NYSE American Company Guide) to protect existing shareholders from excessive dilution without their consent.
• The commitment from the related-party lender to vote in favor of the shareholder approval is a positive, but the reliance on related-party financing itself, while not uncommon for smaller biotechs, can sometimes be viewed less favorably than arm's-length transactions by institutional investors.

Corporate Governance

Related Party Transactions

• Serina Therapeutics, Inc. entered into an unsecured convertible note agreement for up to $20 million with Gregory H. Bailey, M.D., a member of the company's Board of Directors.
• Gregory H. Bailey, M.D. is a designee of Juvenescence Limited and its affiliates, which are the largest holders of the company's common stock.
• The transaction was reviewed and approved by a Special Committee comprised solely of independent and disinterested directors.

Stakeholder Impact

• Shareholders: Potential for significant dilution upon conversion of the note and exercise of warrants. However, the financing provides capital to advance the clinical program, which could increase long-term shareholder value if successful. Shareholder approval is required for significant dilution.
• Creditors: The convertible note constitutes senior unsecured obligations, ranking pari passu with other unsecured indebtedness, potentially impacting the recovery of other unsecured creditors in a default scenario.
• Employees: Continued funding for the clinical program supports ongoing research and development activities, potentially stabilizing employment and future growth opportunities.
• Patients: The financing directly supports the SER-252-1b registrational clinical study for advanced Parkinson's Disease, potentially leading to a new treatment option.

Next Steps

• Draw Tranche 1 Loan (up to $5 million) by September 30, 2025.
• Achieve Milestone 2: Enrollment of the first patient in the SER-252-1b registrational clinical study by December 15, 2025.
• Achieve Milestone 3: Enrollment of the second patient in the SER-252-1b study.
• Achieve Milestone 4: Dosing of the last patient in Cohort 1 of the SER-252-1b study by March 15, 2026.
• Achieve Milestone 5: Data Monitoring and Safety Board (DMSB) approval to proceed with dosing patients in Cohort 2 of the SER-252-1b study by April 30, 2026.
• Hold an annual or special meeting of shareholders by approximately December 8, 2025, to obtain approval for equity issuances exceeding 19.99% of outstanding common stock.
• Submit a resale registration statement to the SEC by January 31, 2026, covering the shares issuable upon conversion of the note and exercise of warrants.

Key Dates

Recommendation

The financing provides essential capital for Serina Therapeutics to advance its critical SER-252-1b clinical study for Parkinson's Disease, which is a positive development for a clinical-stage biotech. The milestone-based funding structure and the commitment from a significant insider investor (board member and largest shareholder) are encouraging. However, the high interest rate, the potential for substantial dilution from the convertible note and warrants, and the inherent risks associated with clinical trial success and regulatory approval warrant a cautious approach. The requirement for shareholder approval for full equity issuance also adds a layer of uncertainty. Given these factors, a 'hold' recommendation is appropriate, advising investors to monitor clinical progress, shareholder approval outcomes, and the company's financial health closely before making further investment decisions.

Keywords

Serina Therapeutics, SER-252, Parkinson's Disease, Convertible Note, Warrants, Clinical Study, Biotechnology, Pharmaceuticals, SEC Filing, Capital Raise, Related Party Transaction, NYSE American, Clinical Milestones, Equity Financing